Payers weigh in on what's driving drug price hikes; Pfizer lays out plan to widen access to hundreds of medicines

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: Pfizer says it will widen access to hundreds of off-patent medicines in low-income countries By Ed Silverman Adobe Pfizer's effort comes amid harsh criticism of the pharmaceutical industry for failing to do more to widen access to its products. Read More STAT+: Large health insurers lowered barriers to fair access to some drugs, analysis finds By Ed Silverman Adobe A new analysis suggests patients still face significant barriers to access because of policy choices made by payers. Read More STAT+: Major purchasers predict expensive new therapies will keep driving drug price hikes By Ed Silverman Adobe The impact of the Inflation Reduction Act is expected to be modest in terms of implications for drug pricing and use, a new survey found. Read More Sponsored Insight by STAT Madness Apply for STAT Madness! Has your institution innovated in ways worth celebrating? Submit your application to be considered for our bracket-style tournament to find the best innovations in science and medicine here. STAT+: After four years of big talk, mega startup Sana prepares to deliver some data By Jason Mast Adobe CEO Steve Harr acknowledges setbacks but says Sana will start clinical trials of novel treatments for both cancer and diabetes this year. Read More STAT+: Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer By Matthew Herper NIAID Success of the company's Phase 3 RSV vaccine trial sets the stage for a competition with drug giants GlaxoSmithKline and Pfizer. Read More Tuesday, January 17, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser